Finanzen von Cadrenal Therapeutics Inc (CVKD)CVKDCadrenal Therapeutics Inc

Evaluating the bottom line, Cadrenal Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -275.16%, provide a clear picture of how effectively CVKD converts its operational activities into shareholder value.

In the context of the broader market, CVKD competes directly with industry leaders such as LABT and GOVX. With a market capitalization of $5.49M, it holds a significant position in the sector. When comparing efficiency, CVKD's gross margin of N/A stands against LABT's N/A and GOVX's N/A. Such benchmarking helps identify whether Cadrenal Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Cadrenal has faced significant financial challenges, with a net income loss of -2,496,540 USD in the latest quarter and a 1-year change in stock price of -87.59%.